Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13614965 | 0.90 | MAPK14 (0.49) | MAPK14NR1H4HPGDALDH1A1LCK | |
| SCHEMBL10950068 | 0.88 | MAPK14 (0.48) | MAPK14NR1H4HPGDALDH1A1LCK | |
| SCHEMBL4151138 | 0.85 | NR1H4 (0.61) | MAPK14NR1H4HPGDNPC1KMT2A | |
| SCHEMBL18781295 | 0.84 | PLK1 (0.56) | HPGD | |
| SCHEMBL18661954 | 0.82 | MAPK14 (0.51) | MAPK14NR1H4HPGDALDH1A1LCK | |
| SCHEMBL13753864 | 0.81 | HPGD (0.68) | MAPK14HPGDALDH1A1NPC1KMT2A | |
| SCHEMBL5707117 | 0.81 | HDAC1 (0.67) | MAPK14NR1H4HPGDALDH1A1LCK | |
| SCHEMBL12958467 | 0.81 | MAPK14 (0.50) | MAPK14NR1H4HPGDALDH1A1LCK | |
| SCHEMBL13265891 | 0.81 | KDM4E (0.58) | MAPK14HPGDALDH1A1NPC1KMT2A | |
| SCHEMBL3250190 | 0.81 | MAPT (0.59) | MAPK14NR1H4HPGDALDH1A1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040022834-A1 | Pharmaceutical oxan preparation | PIERRE FABRE MEDICAMENT (FR) | 2004-02-05 | — | — | US | claimed |
| EP-1322298-A1 | PHARMACEUTICAL OXAN PREPARATION | PIERRE FABRE MEDICAMENT (FR) | 2003-07-02 | — | — | EP | claimed |
| WO-2002026216-A1 | PHARMACEUTICAL OXAN PREPARATION | PIERRE FABRE MEDICAMENT (FR) | 2002-04-04 | — | — | WO | claimed |
| WO-2001070224-A2 | RILMENIDINE DRESSING AND METHOD FOR PREPARING SAME | PIERRE FABRE MEDICAMENT (FR) | 2001-09-27 | — | — | WO | claimed |
| US-4164561-A | CITRAL, CITRONELLA OIL, DIETHYLTOLUAMIDE | HAUTMANN HORST (DE) | 1979-08-14 | — | — | US | claimed |
| JP-7112902-A | — | — | None | — | — | JP | disclosed |
| WO-2014011695-A2 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20040022834-A1 | Pharmaceutical oxan preparation | PIERRE FABRE MEDICAMENT (FR) | 2004-02-05 | — | — | US | disclosed |
| EP-1322298-A1 | PHARMACEUTICAL OXAN PREPARATION | PIERRE FABRE MEDICAMENT (FR) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002026216-A1 | PHARMACEUTICAL OXAN PREPARATION | PIERRE FABRE MEDICAMENT (FR) | 2002-04-04 | — | — | WO | disclosed |
| WO-2001070224-A2 | RILMENIDINE DRESSING AND METHOD FOR PREPARING SAME | PIERRE FABRE MEDICAMENT (FR) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001041702-A2 | ZINC THIOSALICYLATE, DERMATOLOGICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR IN THE FORM OF A SELF-ADHESIVE DEVICE AND METHOD FOR PREPARING SAME | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2001-06-14 | — | — | WO | disclosed |
| JP-H07112902-A | COCKROACH REPELLENT COMPOSITION | DAIWA KAGAKU KOGYO KK | 1995-05-02 | — | — | JP | disclosed |
| EP-0067533-B1 | PROCESS OF SPRAY MICRO-ENCAPSULATION AND COMPOSITION FOR USE THEREIN | ENVIRONMENTAL CHEMICALS, INC. (US) | 1986-03-12 | — | — | EP | disclosed |
| EP-0067533-A1 | Process of spray micro-encapsulation and composition for use therein | ENVIRONMENTAL CHEMICALS, INC. (US) | 1982-12-22 | — | — | EP | disclosed |
| US-4353962-A | USING AN ACRYLIC POLYMER | ENVIRONMENTAL CHEMICALS, INC. (US) | 1982-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040022834-A1 | Pharmaceutical oxan preparation | OXA1L, OSTC, OTC | MAPK14 4268/4885NR1H4 1628/4885HPGD 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.